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Introduction
Zinc is an essential element for life and has been established as being of great importance in humans. It is an essential ion in cells and is a cofactor for more than 300 enzymes. Zinc deficiency can have detrimental effects in humans e.g. in acrodermatitis enteropathica, an inherited defect in which zinc absorption from the intestine is reduced resulting in retarded growth, hypogonadism, skin & ophthalmic lesions, and a deficiency in cell-mediated immunity.
However, an excess of zinc can be toxic to cells, hence the regulation of cellular zinc levels is of great importance.
The concentrations of zinc in normal and diseased tissue from a number of organs have been measured. Reddy et al (2008) , used particle induced x-ray emission (PIXE) techniques to carry out trace element analysis on samples of kidney and stomach carcinoma. The study reported higher levels of zinc in the cancerous tissue of the kidney compared to normal tissue, while in the stomach the zinc levels were reported to be lower in the cancerous tissue. Kwiatek et al (2002) also investigated trace element levels in cancerous kidney by using Synchrotron Radiation Induced X-ray Emission (SRIXE), reporting a lower concentration of zinc in the cancerous liver when compared to normal tissue. Al-Ebraheem et al (2009) measured concentrations of zinc in both kidney and liver tumours and compared them with normal kidney and liver tissue using xray fluorescence. The study reported that zinc was reduced in liver and kidney tumours by 63% and 26%, respectively. Tashiro et al (2006) studied levels of zinc in the liver and reported lower levels in the tumour tissue compared to non tumour tissue. Carvalho and Marques (2001) also looked at liver tissue using x-ray fluorescence and reported lower values of Zn in liver cirrhosis samples compared with healthy tissues. Work by our group (Farquharson et al 2008) carried out XRF analysis on secondary colorectal liver metastases and reported a significant lowering of zinc levels (p<0.01) in the cancer tissue when compared to the normal surrounding liver tissue.
The role of zinc in prostate cancer has been of interest in recent years and there have been a number of studies looking at the concentrations in cancer and normal prostate tissue. IdeEktessabi et al (2002) used a synchrotron X-ray fluorescence microbeam to measure levels of zinc in cancerous and normal tissues of the human prostate. In the cancerous tissues, zinc was reported at levels of 89-221 ppm in the adenocarcinoma and 44-713 ppm in the stroma. In the normal tissues, zinc was detected at 158-474 ppm in the epithelial cells and 101-180 ppm in the stroma.
In the case of breast cancer there have been a number of studies looking at trace element levels. Garg et al (1990) used neutron activation analysis (INAA) to study breast tumours and healthy breast tissue and reported elevated levels of all measured elements in the tumour samples including Fe, Cu and Zn. Ng et al (1997) also used INAA in a similar study on both healthy and cancerous breast tissue and reported all measured elements increased in the tumour tissue again including Fe, Cu and Zn. Total reflection XRF was utilized by Majewska et al (1997) to compare benign and malignant breast tumours and reported increased levels of most elements measured including K, Ca, Fe, Cu, Zn, Se and Rb. The same technique was used by Kubala-Kukus et al (2007) in a study that compared malignant and benign tumours in breast and reported higher levels of all elements measured in malignant tumours with the exception of Cu which was found to be reduced. Majewska et al (2007) carried out a very similar study again using total reflectio n XRF and reported significant higher levels of Fe and Se in malignant breast tissue compared to benign tissue. Geraki et al (2002 Geraki et al ( , 2004 used synchrotron radiation to evaluate the levels of K, Fe, Cu and Zn in 40 matched pairs of normal breast tissue and tumour tissue reporting significant higher levels of all elements in the cancer samples. A recent paper by Silva et al (2008) has reported elevated levels of Ca, Fe, Cu and Zn in tumour breast tissue compared to healthy tissue from the same breast. More recent work by our group has made use of synchrotron radiation xray fluorescence (SRXRF) micro probes to map the distribution of metals including zinc in samples of invasive ductal carcinoma of breast (Farquharson et al 2008 , Geraki et al 2007 . The advantage of mapping the distribution of metals in the tissue compared to measuring levels in a lump of tissue can be seen by example when comparing the results presented for iron. Our work on iron levels in breast cancer using a lump of tissue have reported higher levels in the tumour compared to healthy tissue. On average this appears to be the case but our mapping technique has shown that there are some cases where the iron levels are decreased in the tumour compared to surrounding normal tissues and seems in some way to be case specific.
Cellular concentrations of zinc are strictly controlled by zinc transporter proteins that fall i nto two families. One is the ZnT family (SLC30A) that are responsible for the control of zinc efflux, transporting zinc out of the cells or into intracellular compartments. The human ZnT f amily contains 9 genes. The second is the ZIP family (SLC39A) that control the zinc influx, transporting zinc into the cell cytoplasm from outside the cell or from intracellular regions. The human ZIP family has 14 genes. Furthermore, it has been reported that certain members of the ZIP transporter family play a role in various disease states suggesting that an uncontrolled expression of zinc transporters could lead to an uncontrolled growth such as occurs in cancer (Taylor et al 2007) . There is one sub group of the ZIP family that contains 9 genes and is known as the LIV-1 subfamily. Eight of these are transmembrane proteins residing on the plasma membrane of cells and transport zinc into the cell, but one member is situated on intracellular membranes resulting in it transporting zinc from intracellular compartments to the cytoplasm.
Oestrogen is a primary female sex hormone that acts by binding and activating protein molecules called oestrogen receptors (ER). Oestrogen is important for the normal growth and development of the mammary gland and breast cancer progression is influenced by oestrogen, (Anderson 2002 ). An assessment of ER expression within the tumour cells can be stated to be ER negative when the tumour does not show ER expression, or ER positive when the tumour shows expression of ER (Badve and Nakshatri 2009) . ZIP7 has been shown to be regulated by oestrogen and has ele vated expression in oestrogen receptor positive (ER+ve) cancer of the breast and an inverse relationship to epidermal growth factor receptor (EGFR) status (Taylor et al 2007) . Given its role as a regulator of zinc influx, the increased levels of LIV-1 could lead to a higher concentration of zinc in ER+ve cancers compared to ER-ve cancers. We therefore investigated the zinc levels in human primary tumour tissue compared to surrounding stromal tissue in samples of both ER +ve and ER -ve invasive ductal carcinoma of breast. In addition to using ER status as a marker, we also compared the levels using EGFR status, nodal status, tumour size, tumour grade and menopausal status.
Methodology
The data was collected using Synchrotron Radiation X-Ray Fluorescence (SRXRF) microprobes at three locations. 1. The FLUO beamline at ANKA, Karlsruhe, Germany. 2. Beamline L, Hasylab, DESY, Hamburg and beamline I18 at DIAMOND in the UK. The experimental set up took on a similar form at all three facilities with specific details given below. At DESY the data was collected using the Synchrotron X-Ray Fluorescence Microprobe at Hasylab, beamline L.
The bending magnet source produces a white beam that is monochromated by a double multilaye r monochromator. The beam is focussed by a polycapillary half lens (X-Ray Optical Systems, Inc). At the energy of 11 keV used at DESY for this study an on sample spot size of approximately 15µm x 15µm was obtained. A stepwise scan was used with the measurement time at each point being 5 seconds. The fluorescence signal is recorded using a Peltier cooled energy dispersive Si drift detector (Radiant, Vortex). The data is further analysed using AXIL, a programme that fits the element K α and K β peaks under consideration taking into account line overlaps and subtracts background. In this case the data is normalised to the varying incident radiation intensity via an ionisation chamber measurement pre sample.
The data collected at ANKA using the FLUO beamline which again has a bending magnet source monochromated using double multilayer monochromator. A poly capillary lens gives an on sample spot size of approximately 3µm x 5µm at an energy of 10.5keV. The data is collected us ing a Si(Li) energy dispersive detector (Oxford Instruments) and processed using AXIL. Here the data collection time is allowed to vary according to the length of time for a pre set amount of radiation to reach the sample at each measurement point.
The undulator-produced beam on I18 at Diamond is focused by a pair of Kirkpatrick-Baez mirrors after being monochromatised by a double-crystal monochromator. On this occasion the on sample size of the beam was approximately 5µm x 5µm. A 9-element Ortec germanium detector was used while the treatment of the spectra was accomplished using PyMCA (Solé et al 2007) . The incident beam energy was 11 keV and the collection time per measurement point was 4 seconds. Note this facility is constant top up and normalisation to beam intensity was not required as variation was negligable.
At all facilities a 45° geometry was used between the incident radiation beam and the sample, and a 90° geometry between the incident beam and the detector. A schematic of the experimental set up is shown in figure 1 . A novel feature of this work was that the samples were in the form of formalin fixed paraffin embedded Tissue Micro Arrays (TMAs) consisting of 1.0mm diameter sections of tissue mounted in arrays of size 5x4 samples. Up to six of these arrays are mounted on any one slide. The samples were pre-screened in order to identify those suitable for this study, i.e. that they were invasive ductal carcinoma (IDC) and the ER status identified so that as near equal numbers of each classification could be used. Two slices were cut from the paraffin block, one being 10µm thick the other being 5µm thick and cut adjacent to the 10µm slice. The 10µm thick slice was mounted on 4µm ultralene XRF film that was stretched and held in a bespoke frame keeping the sample slice as flat as possible. This is important in that it enabled the sample to be kept in a constant plane with respect to the incident x-ray beam. The 5µm thick slice was mounted on a standard glass slide and then stained using
Haematoxylin and Eosin (H & E)
. This slide was then optically imaged to produce high resolution images which clearly identify tumour regions in the samples and can be used as a reference slide for the elemental distribution maps produced from the experimental slide. Maps of the zinc distribution were produced and could be compared to the H and E reference images, which enabled regions of interest to be set on the maps encompassing tumour cell regions and regions of surrounding non tumour tissue. Each pixel represents a value that was the total zinc K a count normalised for the intensity of the incident beam. Statistics could then be extracted from these regions including mean normalised pixel value, maximum and minimum normalised pixel value and the standard deviation. Figure 2 shows a map of the zinc distribution compared to the stained reference image with the region of interests set for this particular sample. When comparing the zinc levels between the ER+ve and the ER-ve groups it was found that the mean total zinc content for each sample (i.e. tumour and surrounding regions) was approximately 60% higher in the ER+ve samples than the ER-ve samples. There was also difference in the mean levels of zinc in the tumour regions with ER+ve samples having approximately 80% more zinc than ER-ve samples. The m ean levels of zinc in the non tumour regions did not differ significantly although on average the increase in the ER+ve samples was approximately 10% more than the ER-ve samples. The zinc levels in the tumour and surrounding regions of the ER+ve samples were compared. For all of the samples, the tumour tissue zinc levels were higher than the corresponding surrounding non tumour tissue zinc, the difference being very significant (p<0.001 t-test). For the ER-ve samples, the zinc levels were higher in the tumour tissue for all samples, however the analysis revealed that the difference was not significant (P=0.07). Figure 4 shows the correlation between the levels of zinc in the non tumour tissue and tumour tissue regions in the samples. There is a similar correlation in the ER+ve and ER-ve samples (Pearson product moments correlation squared, R 2 =0.35 and 0.38 respectively).
The average values for the percentage increase in zinc in tumour regions with respect to surrounding regions for the ER+ve samples was 148%, while for the ER-ve samples was 89%. Table 1 shows a summary of the analyses for both sets of data. The higher percentage increase in zinc values in the ER+ve samples compared to the ER-ve samples was significantly different (P<0.01). The EGFR, nodal and menopausal markers showed no significant differences between status.
Beside the ER status result, the only significant results were found in the tumour size and tumour grade. The size of tumour was split into three groups, 0-1.5cm, 1.5-3.0cm and greater than 3.0cm. The significant difference was found between the samples in grouping 0-1.5 and the samples in grouping 1.5-3.0. The tumour grade was split into grades 1, 2 and 3 with a significant difference found between tumours with grades 1 and 2. 
Conclusion
To the best of our knowledge, this is the first study to map the distribution of zinc and be able to correlate the findings with important biological variables. The technique has the advantage of being able to discriminate the metal levels between tumour tissue and the surrounding stroma tissue. The increase in zinc levels in ER+ve invasive ductal carcinoma using a micro-mapping technique has not been previously described. A likely explanation of these data is related to the elevated leve ls of the zinc transporter family reported in ER+ve cancers. These transporters exist on the plasma membrane and the higher levels result in an increase influx of zinc into the tumour cells. The observation that the zinc levels in the normal regions of both ER+ve and ER-ve were approximately the same would suggest that there is an uninterrupted supply of zinc to the tissue.
However, if there is an inverse relationship for the zinc transporter, ZIP7 with EGFR status i.e.
lower amounts of zinc transporter in EGFR+ve cancers it could be expected that zinc concentrations may be lower in these cancers compared to EGFR-ve cancers. However t his study found no difference in zinc levels between these groups, a possible explanation being that zinc is transported to the tumour cells using an alternative transport pathway. It should be noted that some zinc transporters on the plasma membrane do not show this inverse relationship i.e.
ZIP5, ZIP10 and ZIP14 (Taylor et al 2007) , and so may provide a way of supplying zinc.
An uptake of zinc could be clinically relevant and this study shows the feasibility of assessing this in large numbers of small samples. Antihormone drugs such as tamoxifen and aromatase inhibitors are used to treat ER+ve breast cancers but the tumours often develop resistance to these drugs. In some cases regrowth of the tumour and a progression in the disease is via the activation of members of the EGFR family such as HER2. It has been proposed that inhibition of the zinc transporter reduces activation of the EGFR signaling by reducing zinc levels and therefore offers way of preventing further development of the cancer (Taylor et al 2008) . Zinc chelating agents are a possible treatment as they have been shown to exhibit antitumor effects in human breast cancer by inducing apoptosis (Hashemi et al 2007) . However, these chelators may result in significant cytotoxic effects. These toxic effects may also be via inhibition of the antioxidant induction of superoxide dismutase (SOD). It is clear it would be desirable to select the subgroup of patients with high tumour zn levels for such trials, rather than treat all patients.
This method and results show for the first time the relationship of zn in breast tumours to breast tumour biology and opens the way for further investigations of the mechanism of zinc uptake in clinical samples and assays to select and monitor zn chelation therapy. It is clear that zinc plays an important role in the development of breast and possibly other cancers and is an element that warrants further study.
